Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Control Release ; 142(3): 332-8, 2010 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-19925836

RESUMO

Though stents are deployed in diseased arteries drug distribution has only been quantified in intact, non-diseased vessels. We correlated steady-state arterial drug distribution with tissue ultrastructure and composition in abdominal aortae from atherosclerotic human autopsy specimens and rabbits with lesions induced by dietary manipulation and controlled injury. Paclitaxel, everolimus, and sirolimus depositions in the human aortae were maximal in the media and scaled inversely with lipid content. Net tissue paclitaxel and everolimus levels were indistinguishable in mildly injured rabbit arteries independent of diet. Yet, serial sectioning of cryopreserved arterial segments demonstrated a differential transmural deposition pattern that was amplified with disease and correlated with the expression of their intracellular targets, tubulin and FKBP-12. Tubulin distribution and paclitaxel binding increased with vascular injury and macrophage infiltration, and were reduced with lipid content. Sirolimus analogs and their specific binding target FKBP-12 were less sensitive to alterations of diet in mildly injured arteries, presumably reflecting a faster transient response of FKBP-12 to injury. The data demonstrate that disease-induced changes in the distribution of drug-binding proteins and interstitial lipid alter the distribution of these drugs, forcing one to consider how disease might affect the evaluation and efficacy of the local release of these and like compounds.


Assuntos
Aterosclerose/patologia , Sistemas de Liberação de Medicamentos/métodos , Stents Farmacológicos , Paclitaxel/farmacocinética , Sirolimo/análogos & derivados , Túnica Íntima/ultraestrutura , Animais , Aorta Abdominal/efeitos dos fármacos , Aorta Abdominal/metabolismo , Aorta Abdominal/ultraestrutura , Aterosclerose/tratamento farmacológico , Aterosclerose/metabolismo , Colesterol/metabolismo , Modelos Animais de Doenças , Everolimo , Humanos , Masculino , Paclitaxel/administração & dosagem , Paclitaxel/uso terapêutico , Ligação Proteica , Coelhos , Sirolimo/administração & dosagem , Sirolimo/farmacocinética , Sirolimo/uso terapêutico , Distribuição Tecidual , Túnica Íntima/efeitos dos fármacos , Túnica Íntima/metabolismo
2.
Proc Natl Acad Sci U S A ; 101(25): 9463-7, 2004 Jun 22.
Artigo em Inglês | MEDLINE | ID: mdl-15197278

RESUMO

Endovascular drug-eluting stents have changed the practice of medicine, and yet it is unclear how they so dramatically reduce restenosis and how to distinguish between the different formulations available. Biological drug potency is not the sole determinant of biological effect. Physicochemical drug properties also play important roles. Historically, two classes of therapeutic compounds emerged: hydrophobic drugs, which are retained within tissue and have dramatic effects, and hydrophilic drugs, which are rapidly cleared and ineffective. Researchers are now questioning whether individual properties of different drugs beyond lipid avidity can further distinguish arterial transport and distribution. In bovine internal carotid segments, tissue-loading profiles for hydrophobic paclitaxel and rapamycin are indistinguishable, reaching load steady state after 2 days. Hydrophilic dextran reaches equilibrium in several hours at levels no higher than surrounding solution concentrations. Both paclitaxel and rapamycin bind to the artery at 30-40 times bulk concentration. Competitive binding assays confirm binding to specific tissue elements. Most importantly, transmural drug distribution profiles are markedly different for the two compounds, reflecting, perhaps, different modes of binding. Rapamycin, which binds specifically to FKBP12 binding protein, distributes evenly through the artery, whereas paclitaxel, which binds specifically to microtubules, remains primarily in the subintimal space. The data demonstrate that binding of rapamycin and paclitaxel to specific intracellular proteins plays an essential role in determining arterial transport and distribution and in distinguishing one compound from another. These results offer further insight into the mechanism of local drug delivery and the specific use of existing drug-eluting stent formulations.


Assuntos
Proteínas Sanguíneas/metabolismo , Artéria Carótida Interna/metabolismo , Paclitaxel/sangue , Sirolimo/sangue , Animais , Bovinos , Dextranos/sangue , Dextranos/farmacocinética , Cinética , Músculo Liso Vascular/metabolismo , Paclitaxel/farmacocinética , Sirolimo/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...